Thrombophilia does not increase risk for neonatal complications in preterm infants

Summary

The association between thrombophilia and neonatal complications was evaluated in a single-center prospective study. Prevalence of genetic prothrombotic markers (FVL, MTHFR, FIIG20210A) and levels of plasma homocysteine were assayed in 166 premature (mean gestational age: 30.9±2.3 weeks) and low birth weight (mean weight: 1327±319 grams) infants. The incidence of any neonatal complications was compared in infants with and without thrombophilia. A total of 38 infants were defined as “thrombophilic” due to heterozygous FVL (n=4) and/or FIIG20210A (n=8, including one case of combination with FVL) or homozygous 677T MTHFR (n=22) or homo-cysteine plasma levels above 15µmole/liter. Neonatal complications included: small for gestational age (28.8%), respiratory distress syndrome (51.8%), broncho-pulmonary dysplasia (10.2%), patent ductus arteriosus (12.7%), intraventricular hemorrhage (17%), periventricular leucomalacia (8.4%), retinopathy of prematurity (15.1%) and necrotizing enterocolitis in 1.2% of infants. No thrombosis was documented. The prevalence of perinatal complications and the severity of diseases were similar among infants with or without thrombophilia (p=0.564). Our data suggest that preterm infants with thrombophilia are not at increased risk for developing neonatal complications.

Keywords

Homocysteine - neonates - preterms - SGA - thrombophilia

^* Both authors contributed equally to the manuscript, as first authors from different disciplines

• References

• 1 Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Eng J Med 2001; 344: 1222-31.
• 2 Salomon O, Steinberg DM, Zivelin A. et al Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism. Arteriscler Thromb Vasc Biol 1999; 19: 511-8.
• 3 Dalback B. New molecular insights of thrombophilia: resistance to activated protein C caused by Arg506 to Gln. Mutation in factor V as pathogenetic risk factor for venous thrombosis. Thromb Haemost 1995; 74: 139-48.
• 4 Poort SR, Rosendal FR, Rewifman PH. et al A common genetic variation in the 3’ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
• 5 Frosst P, Bloom HJ, Milos R. et al A candidate genetic risk factor for vascular disease: a acommon mutation in methylene-tetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
• 6 Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998; 158: 2101-6.
• 7 Grandone E, Margaglione M, Collazio D. et al Genetic susceptibility to pregnancy-related thromboembolism: roles of factor V Leiden, prothrombin G20210A and methylenetetrahydrofolatereductase C677T mutations. Am J Obstet Gynecol 1998; 179: 1324-8.
• 8 Kuperminc MJ, Eldor A, Steinman N. et al Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Eng J Med 1999; 341: 384
• 9 Martinelli I, Taioli E, Cetin I. et al Mutations in coagulation factors in women with unexplained late fetal loss. N Eng J Med 2000; 343: 1015-8.
• 10 Von-Kries R, Junker R, Oberle D. et al Foetal growth retardation in children with prothrombotic risk factors. Thromb Haemost 2001; 86 (04) 1012-6.
• 11 Infante-Rivard C, Rivard GE, Yotov VW. et al Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N Eng J Med 2002; 347 (01) 19-25.
• 12 Pet J, Hiltunen L, Fellman V. Increased risk of intraventricular hemorrhage in preterm infants with thrombophilia. Ped Res 2001; 49 (05) 643-6.
• 13 Aronis S, Platokouki H, Photopoulos S. et al Indications of coagulation and/or fibrinolytic system activation in healthy and sick very low birth weight neonates. Biol Neonate 1998; 74 (05) 337-44.
• 14 Smith RA, Skelton M, Howard M. et al Is thrombophilia a factor in the development of hemiplegic cerebral pasy?. Dev Med Chil Neurol 2001; 43 (11) 724-30.
• 15 Araki A, Sako Y. Determination of free and total homocysteine in human plasma in high-performance liquid chromatography with fluorescence detection. J Chromatog 1987; 422: 43-52.
• 16 Hongsprabhas P, Saboohi F, Arenda JV. et al Plasma homocysteine concentrations of preterm infants. Biol Neonate 1999; 76: 65-71.
• 17 Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost 1995; 74: 415-25.
• 18 Andrew M, David M, Adams M, Ali K. et al Venous thromboembolic (VTE) complications in children: first analyses of the Canadian registry of VTE. Blood 1994; 83: 1252-7.
• 19 Heleen Van-Omen C, Heijboer B, Buller HR. et al Venous thromboembolism in childhood: a prospective two-year registry in the Netherlands. J Ped 2001; 139: 676-81.
• 20 Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics 1995; 96: 939-43.
• 21 Nowak-Gottl U, Von-Kries R, Gobel U. Neonatal symptomatic thromboembolism in Germany: two year survey. Arch Dis Child Fetal Neonatal ed 1997; 76: F163-F167.
• 22 DeVeber G, Andrew M, Adams C. et al Cerebral sinovenous thrombosis in children. N Eng J Med 2001; 345: 417-23.
• 23 Heller C, Schobess R, Kurnik K. et al Abdominal thrombosis in neonates and infants: role of prothrombotic risk factors-a multicenter case-control study. BJH 2000; 111: 534-9.
• 24 Uttenreuther-Fischer MM, Vetter B, Hellmann C. et al Pediatric thromboembolism; the influence of non-genetic factors and the role of activated protein C resistance and protein C deficiency. Eur J Ped 1996; 156: 227-81.
• 25 Schwartz DS, Gettner PA, Konstantino MM. et al Umbilical venous catheterization and the risk of portal vein thrombosis. J Peds 1997; 131: 760-2.
• 26 Resnik R. Intrauterine growth restriction. Obstet Gynecol 2002; 99: 490-6.
• 27 Schmidt BK. Antithrombin III deficiency in neonatal respiratory distress syndrom. Blood Coagul Fibrinolysis 1994; 5: S13-7. discussion S59-64
• 28 Hutter JJ, Hathaway WE, Wayne ER. Hematologic abnormalitiesin severe neonatal necrotizing enterocolitis. J Pediatr 1976; 88: 1026-31.
• 29 Hussain N, Clive J, Bhandari V. Current incidences of retinopathy of prematurity. 1989-1997 Pediatrics 1999; 104: 26e
• 30 Seiberth V, Linderkamp O. isk factors in retinopathy of prematurity. A multivariate analysis. Ophthalmologica. 2000; 214: 131-5.
• 31 Shweki D, Itin A, Soffer D. et al Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-5.
• 32 Hellstrom H, Perruzzi C, Ju M. et al Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. PNAS 2001; 98 (10) 5804-8.
• 33 Mintz-Hittner HA, Miyashiro MJ, Knoght-Nana DM. et al Vitroretinal findings similar to retinopathy of prematurity in infants with compound heterozygous protein S deficiency. Ophthalmology 1999; 106: 1525-30.
• 34 Riikonen R, Kekomki R. Resistance to activated protein C in childhood hydrocephalus. Thromb Haemost 1998; 79: 1059-60.